Grifols (GRFS) Cash from Investing Activities (2010 - 2020)

Grifols (GRFS) posted Cash from Investing Activities of -$125.1 million for Q1 2020, up 71.26% quarter-over-quarter from -$435.2 million in Q4 2019, and up 56.61% year-on-year from -$79.9 million in Q2 2019.

Grifols (GRFS) Cash from Investing Activities (2010 - 2020) Analysis & Trends

Grifols (GRFS) has reported Cash from Investing Activities for 10 consecutive years, with -$125.1 million the latest figure, recorded in Q1 2020.

  • Cash from Investing Activities for Q1 2020 came in at -$125.1 million, up 56.61% year-over-year; the trailing twelve-month figure through Mar 2020 was -$94.3 million (down 223.87% YoY), and the FY2025 annual result was -$674.0 million, down 171.19% from the prior year.
  • Cash from Investing Activities was -$125.1 million for Q1 2020 at Grifols, up from -$435.2 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $2.4 billion in Q4 2017 and troughed at -$798.7 million in Q3 2016.
  • Average Cash from Investing Activities over 5 years is $281.0 million, with a median of -$120.2 million recorded in 2016.
  • Year-over-year, Cash from Investing Activities tumbled 1045.5% in 2016 and surged 2116.99% in 2017.
  • Over 5 years, Cash from Investing Activities stood at -$120.2 million in 2016, then soared by 2116.99% to $2.4 billion in 2017, then tumbled by 68.9% to $754.2 million in 2018, then sank by 157.7% to -$435.2 million in 2019, then jumped by 71.26% to -$125.1 million in 2020.
  • Per Business Quant data, the three most recent Cash from Investing Activities figures were -$125.1 million in Q1 2020, -$435.2 million in Q4 2019, and -$288.3 million in Q1 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -3.92 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -1.04 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn -574.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -1.79 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -10.21 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -716.00 Mn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 1.77 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 785.00 Mn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Grifols - - - -

Historic Data

Download Data
DateValue
Mar 31, 2020 -125.09 Mn
Mar 31, 2020 -125.09 Mn
Dec 31, 2019 -435.16 Mn
Dec 31, 2019 -435.16 Mn
Mar 31, 2019 -288.25 Mn
Mar 31, 2019 -288.25 Mn
Dec 31, 2018 754.17 Mn
Dec 31, 2018 754.17 Mn
Jun 30, 2018 -509.49 Mn
Jun 30, 2018 -509.49 Mn
Mar 31, 2018 119.73 Mn
Mar 31, 2018 119.73 Mn
Dec 31, 2017 2.43 Bn
Dec 31, 2017 2.43 Bn
Jun 30, 2017 88.45 Mn
Jun 30, 2017 88.45 Mn
Mar 31, 2017 1.98 Bn
Mar 31, 2017 1.98 Bn
Dec 31, 2016 -120.24 Mn
Dec 31, 2016 -120.24 Mn